Metastatic Liver Disease

Metastatic Liver Disease - Spot the Spread

• Definition: Liver is a frequent site for cancer spread due to its rich dual blood supply (portal vein & hepatic artery).
• Common Primaries: Colorectal (most common, ~50% of liver mets), lung, breast, pancreas, stomach.
• Clinical Features: Often asymptomatic. May present with hepatomegaly, RUQ pain, jaundice (late), weight loss. Elevated LFTs (esp. ALP, GGT).
• Investigations:
  • Imaging: USG (initial), CECT Abdomen (gold standard for detection & staging), MRI (lesion characterization, pre-op planning). PET-CT (evaluating extrahepatic disease).
  • Biopsy: USG/CT-guided if diagnosis is uncertain or primary site is unknown.

⭐ Colorectal cancer is the most common primary tumor that metastasizes to the liver.

Metastatic Liver Disease - Resectability Rules

Error: Failed to generate content for this concept group.

Metastatic Liver Disease - Scalpel Solutions

• Primary Goal: Achieve R0 resection (microscopically negative margins).
• Most Common Primary: Colorectal cancer (CRC); others include neuroendocrine, GIST, sarcoma, melanoma, breast, ovarian.
• Indications for Resection (CRC mets):
  • Resectable primary tumor (or already resected).
  • No unresectable extrahepatic disease (EHD); limited/resectable EHD may be considered.
  • Ability to preserve adequate future liver remnant (FLR) > 20-25% (healthy liver), > 30-40% (chemotherapy-associated liver injury/cirrhosis).
  • Patient fit for major surgery.
• Surgical Approaches:
  • Anatomical resection: Segmentectomy, hemihepatectomy.
  • Non-anatomical (wedge) resection.
  • Laparoscopic or open.
  • Staged procedures: Two-stage hepatectomy, ALPPS (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy).
• Perioperative Chemotherapy: Often used (neoadjuvant/adjuvant) to improve outcomes.

⭐ Resection of colorectal liver metastases can offer a 5-year survival rate of 30-50%, significantly better than systemic therapy alone for eligible patients.

• Prognostic Factors: Number/size of metastases, disease-free interval, margin status, response to chemotherapy. 📌 Fong Score for CRC mets prognosis (older, but foundational).

Metastatic Liver Disease - Beyond the Blade

• Goal: Prolong survival, improve quality of life, or downstage for resection.
• Systemic Therapy: Backbone for widespread disease.
  • Chemotherapy (e.g., FOLFOX/FOLFIRI for CRC mets).
  • Targeted agents (e.g., Bevacizumab, EGFR inhibitors for KRAS wild-type).
  • Immunotherapy (e.g., for MSI-H/dMMR tumors).
• Locoregional Therapies (LRT): For liver-dominant/limited disease.
  • Ablation: Radiofrequency (RFA), Microwave (MWA) for lesions <3-5 cm.
  • Intra-arterial:
    • TACE (Transarterial Chemoembolization): Delivers chemo, induces ischemia.
    • TARE/SIRT (Yttrium-90): Radioactive microspheres.
  • SBRT (Stereotactic Body Radiotherapy): Precise high-dose radiation.

⭐ Neoadjuvant systemic therapy can convert ~15-30% of initially unresectable colorectal liver metastases to resectable status.

High‑Yield Points - ⚡ Biggest Takeaways

• Colorectal cancer (CRC) is the most common primary for liver metastases.
• Surgical resection offers the best survival for CRC liver mets if R0 is achievable.
• Resectability depends on R0 potential, adequate Future Liver Remnant (FLR), and manageable extrahepatic disease.
• Perioperative chemotherapy is standard for resectable CRC liver metastases.
• Ablative therapies (RFA, MWA) treat unresectable or small lesions.
• Portal Vein Embolization (PVE) can ↑ FLR pre-resection.
• Monitor CEA for CRC recurrence and treatment response.